Alexander Cumbo - 25 Jul 2025 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Reporting relationship: Director
Issuer ticker: VERV
Reported as of: 25 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2025, 17:15:04 UTC
Prior SEC filing: 18 Jul 2025
Next SEC filing: 18 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Ashe, as Attorney-in-Fact for Alexander Cumbo

Key filing fact

Alexander Cumbo filed Form 4 for Verve Therapeutics, Inc. (VERV) on 28 Jul 2025.

Key facts

This page summarizes Alexander Cumbo's Form 4 filing for Verve Therapeutics, Inc. (VERV).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Jul 2025, 17:15.

Change

Previous filing in this sequence was filed on 18 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001685994 Primary reporting owner

Cumbo Alexander

Relationship: Director
Address: C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Alexander Cumbo
Signature date: 28 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERV transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -136,139
Change %: -100%
Price
Shares after: 0
Date: 25 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 136,139
Exercise price: $5.02
Footnotes: F1, F2

VERV transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -42,200
Change %: -100%
Price
Shares after: 0
Date: 25 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,200
Exercise price: $5.73
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Alexander Cumbo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

Footnote F2

(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).